Literature DB >> 2299683

Is dose normalization to weight or body surface area useful in adults?

L B Grochow1, C Baraldi, D Noe.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2299683     DOI： 10.1093/jnci/82.4.323

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  17 in total

Review 1.  Body surface area as a determinant of pharmacokinetics and drug dosing.

Authors:  M Sawyer; M J Ratain
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Dose standardisation of anticancer drugs.

Authors:  Anne-Lise Pouliquen; Laurence Escalup; Nathalie Jourdan; Paul Cottu; Pierre Faure; Isabelle Madelaine-Chambrin
Journal:  Int J Clin Pharm       Date:  2011-01-14

Review 3.  Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? A review of theoretical and practical considerations.

Authors:  J J Reilly; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research.

Authors:  J J Reilly; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 5.  Chemotherapy dosing in overweight and obese patients with cancer.

Authors:  Gary H Lyman; Alex Sparreboom
Journal:  Nat Rev Clin Oncol       Date:  2013-07-16       Impact factor: 66.675

Review 6.  Gender aspects of treatment and drug related toxicity in medical oncology.

Authors:  Christine Marosi
Journal:  Wien Med Wochenschr       Date:  2006-10

7.  Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.

Authors:  Terri S Armstrong; Yumei Cao; Michael E Scheurer; Elizabeth Vera-Bolaños; Rochelle Manning; Mehmet F Okcu; Melissa Bondy; Renke Zhou; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

8.  Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

Authors:  Milin R Acharya; Judith E Karp; Edward A Sausville; Kyunghwa Hwang; Qin Ryan; Ivana Gojo; Jurgen Venitz; William D Figg; Alex Sparreboom
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

Review 9.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

Review 10.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.